ATE80998T1 - Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems. - Google Patents

Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.

Info

Publication number: ATE80998T1
Authority: AT; Austria
Prior art keywords: nervous system; central nervous; opiate; nalmefen; medication
Prior art date: 1987-06-05

Application number

AT88905522T

Other languages

English (en)

Inventor

Alan I Faden

Original Assignee

Medicis Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-06-05

Filing date

1988-06-06

Publication date

1992-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22016221&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE80998(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1988-06-06 Application filed by Medicis Corp filed Critical Medicis Corp

1992-10-15 Application granted granted Critical

1992-10-15 Publication of ATE80998T1 publication Critical patent/ATE80998T1/de

Links

210000003169 central nervous system Anatomy 0.000 title abstract 2
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
102000003840 Opioid Receptors Human genes 0.000 abstract 2
108090000137 Opioid Receptors Proteins 0.000 abstract 2
230000003042 antagnostic effect Effects 0.000 abstract 2
208000001738 Nervous System Trauma Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000006698 induction Effects 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
230000000302 ischemic effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
208000028412 nervous system injury Diseases 0.000 abstract 1
229940127240 opiate Drugs 0.000 abstract 1
239000003401 opiate antagonist Substances 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1
230000000472 traumatic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AT88905522T 1987-06-05 1988-06-06 Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems. ATE80998T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US5834087A	1987-06-05	1987-06-05
PCT/US1988/001836 WO1988009603A2 (en)	1987-06-05	1988-06-06	Central nervous system injury treatment with opiate-receptor antagonists
EP19880905522 EP0315681B1 (de)	1987-06-05	1988-06-06	Verwendung von Nalmefen zur Herstellung eines Arzneimittels zur Behandlung der Schädigung des Zentralnervensystems

Publications (1)

Publication Number	Publication Date
ATE80998T1 true ATE80998T1 (de)	1992-10-15

Family

ID=22016221

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT88905522T ATE80998T1 (de)	1987-06-05	1988-06-06	Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.

Country Status (6)

Country	Link
EP (1)	EP0315681B1 (de)
JP (1)	JP2510270B2 (de)
AT (1)	ATE80998T1 (de)
CA (1)	CA1322523C (de)
DE (1)	DE3875065T2 (de)
WO (1)	WO1988009603A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5028612A (en) *	1990-03-22	1991-07-02	Hillel Glover	Method for treating emotional numbness
WO1992018126A1 (en) *	1991-04-10	1992-10-29	Baker Cummins Pharmaceuticals, Inc.	Method of improving donor organ function and preventing reperfusion injury
AU2002231206A1 (en) *	2000-12-21	2002-07-01	The Mclean Hospital Corporation	Treatment of depression
WO2005015242A1 (en) *	2003-08-06	2005-02-17	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with g protein-coupled opioid receptor kappa 1 (opkr1)

1988
- 1988-06-03 CA CA000568687A patent/CA1322523C/en not_active Expired - Fee Related
- 1988-06-06 AT AT88905522T patent/ATE80998T1/de not_active IP Right Cessation
- 1988-06-06 WO PCT/US1988/001836 patent/WO1988009603A2/en not_active Ceased
- 1988-06-06 EP EP19880905522 patent/EP0315681B1/de not_active Expired - Lifetime
- 1988-06-06 DE DE8888905522T patent/DE3875065T2/de not_active Expired - Fee Related
- 1988-06-06 JP JP63505177A patent/JP2510270B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA1322523C (en)	1993-09-28
EP0315681A1 (de)	1989-05-17
JPH02500438A (ja)	1990-02-15
JP2510270B2 (ja)	1996-06-26
DE3875065D1 (de)	1992-11-05
EP0315681B1 (de)	1992-09-30
WO1988009603A2 (en)	1988-12-15
DE3875065T2 (de)	1993-04-01

Similar Documents

Publication	Publication Date	Title
ATE184792T1 (de)	1999-10-15	2-bromomelatonin zur behandlung von schlafstörungen
DE3684190D1 (de)	1992-04-16	Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE58902094D1 (de)	1992-10-01	Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
DE69333321D1 (de)	2004-01-08	Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
ATE185268T1 (de)	1999-10-15	Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ATE204178T1 (de)	2001-09-15	Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69324671D1 (de)	1999-06-02	Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
ATE100320T1 (de)	1994-02-15	Verwendung von thromboxan-a2-rezeptorantagonisten zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von hautkrankheiten.
ES463876A1 (es)	1979-01-01	Procedimiento para la obtencion de nuevos compuestos de n- (2-aminocicloalifatica) fenilacetamida
ATE164067T1 (de)	1998-04-15	Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
DE3780972D1 (de)	1992-09-17	Verwendung von spezifischen n-methyl-d-aspartat-rezeptor-antagonisten zur praevention und behandlung von neurodegeneration.
DE69034149D1 (de)	2004-07-22	Verwendung von Sertralin zur Behandlung von posttraumatischen Stresserkrankungen
DE3855113D1 (de)	1996-04-25	Verwendung von Buspiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung der Alkoholsucht
ATE158183T1 (de)	1997-10-15	Arzneimittel zur behandlung von anxietas
MA19951A1 (fr)	1984-07-01	Procede de preparation d'acides amines tricycliques ainsi que des acides amines bicycliques servant d'intermediaires et leur utilisation comme medicament
ATE137965T1 (de)	1996-06-15	Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
ATE161725T1 (de)	1998-01-15	Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
ES8400742A1 (es)	1983-11-16	Procedimiento de preparacion de las dibenzooxepinas sustituidas y de sus sales de adicion con un acido mineral u organi-co.
ATE217191T1 (de)	2002-05-15	Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE59209728D1 (de)	1999-09-02	VERWENDUNG VON ANTAGONISTEN ODER PARTIELLEN AGONISTEN AM 5-HT 1a-REZEPTOR ZUR BEHANDLUNG UND PRÄVENTION VON KOGNITIVEN STÖRUNGEN
ATE80998T1 (de)	1992-10-15	Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.
DE69330150D1 (de)	2001-05-23	Pharmazeutische Zusammensetzungen zur transdermalen Verabreichung von Melatonin und/oder seine Analoge
DE3852246D1 (de)	1995-01-12	Ethyl-(+)-Apovincaminat zur Behandlung der Demyelinisierung klinischer Erscheinungen autoimmunen Ursprungs.
DE69623316D1 (de)	2002-10-02	Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
ATE69949T1 (de)	1991-12-15	Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.

Legal Events

Date	Code	Title	Description
2008-03-15	REN	Ceased due to non-payment of the annual fee